S01-Pharm-E08: Pfizer 3Q 2024

In this episode of The Quarterly Briefing, we take a deep dive into Pfizer's third quarter performance for 2024. Utilizing AI for smarter, faster, and more engaging analysis, we explore Pfizer's revenue growth, strategies, and challenges. From their leading pneumonia vaccine Prevnar 20 to new treatments for conditions like eczema and vitiligo, we break down Pfizer's diverse portfolio and innovations. Despite facing declines in key drugs and pressure from activist investors like Starboard Value, Pfizer remains focused on balancing short-term financial goals with long-term investments in R&D. We discuss their cost-cutting programs, strategic sell-offs, and the ripple effects of their decisions on the entire pharmaceutical industry. This episode aims to demystify corporate finance and highlight the human impact behind the numbers. Stay curious,  ...